139 related articles for article (PubMed ID: 11781611)
1. High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow.
Klein JL; Hamm C; Dansey RD; Karanes C; Abella E; Cassells L; Peters WP; Baynes RD
Bone Marrow Transplant; 2001 Dec; 28(11):1023-9. PubMed ID: 11781611
[TBL] [Abstract][Full Text] [Related]
2. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Prince HM; Gardyn J; Millward MJ; Rischin D; Francis P; Gates P; Chapple P; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Toner GC
Bone Marrow Transplant; 1999 Mar; 23(5):427-35. PubMed ID: 10100555
[TBL] [Abstract][Full Text] [Related]
4. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
[TBL] [Abstract][Full Text] [Related]
5. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
8. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
[TBL] [Abstract][Full Text] [Related]
9. Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy.
Zimmerman TM; Mick R; Myers S; Bender JG; Lee WJ; Williams SF
Bone Marrow Transplant; 1995 Jun; 15(6):923-7. PubMed ID: 7581092
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel effectively mobilizes peripheral blood CD34+ cells.
Prince HM; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Wall D; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Rischin D
Bone Marrow Transplant; 2000 Sep; 26(5):483-7. PubMed ID: 11019836
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome.
Ahmed T; Kancherla R; Qureshi Z; Mittelman A; Seiter K; Mannancheril A; Puccio C; Chun HG; Bar M; Lipshutz M; Ali MF; Goldberg R; Preti R; Lake D; Durrani H; Farley T
Bone Marrow Transplant; 2000 May; 25(10):1041-5. PubMed ID: 10828863
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
15. Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
García-Rayo S; Pérez-Calvo J; Martín-Algarra S; Martínez-Monge R; Fernández-Hidalgo O; Subirá L; Martínez-Aguillo M; Rebollo J; Azinovic I; Brugarolas A
Bone Marrow Transplant; 2001 Aug; 28(3):235-42. PubMed ID: 11535990
[TBL] [Abstract][Full Text] [Related]
16. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
[TBL] [Abstract][Full Text] [Related]
18. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
[TBL] [Abstract][Full Text] [Related]
19. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer.
Ho AD; Glück S; Germond C; Sinoff C; Dietz G; Maruyama M; Corringham RE
Leukemia; 1993 Nov; 7(11):1738-46. PubMed ID: 7901454
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer.
Hohaus S; Wallwiener D; Martin S; Voso MT; Huober J; Fersis N; Bastert G; Haas R
Semin Oncol; 1998 Apr; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
